Dexamethasone intraocular injection - Icon Bioscience

Drug Profile

Dexamethasone intraocular injection - Icon Bioscience

Alternative Names: DEXYCU; IBI-10090

Latest Information Update: 17 Apr 2017

Price : $50

At a glance

  • Originator Icon Bioscience
  • Class Anti-inflammatories; Antiemetics; Antineoplastics; Fluorinated steroids; Glucocorticoids; Pregnadienetriols; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Ocular inflammation

Most Recent Events

  • 13 Apr 2017 Preregistration for Ocular inflammation in USA (Intraocular)
  • 25 Nov 2016 Dexamethasone intraocular injection is still in phase III trials for Ocular inflammation in USA (Intraocular)
  • 01 Oct 2015 Icon Bioscience initiates a phase III trial for Ocular inflammation in USA (NCT02547623)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top